Patents by Inventor Jon E. Chatterton

Jon E. Chatterton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related Conditions
    Publication number: 20160369283
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
    Type: Application
    Filed: September 2, 2016
    Publication date: December 22, 2016
    Inventors: John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Daniel A. Gamache, Steven T. Miller
  • RNAi-Related Inhibition of TNF-alpha Signaling Pathway for Treatment of Ocular Angiogenesis
    Publication number: 20160326533
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
    Type: Application
    Filed: July 25, 2016
    Publication date: November 10, 2016
    Inventors: Jon E. Chatterton, Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers
  • RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions
    Patent number: 9476047
    Abstract: RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: October 25, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Jon E. Chatterton, Abbot F. Clark, Martin B. Wax
  • RNAi-mediated inhibition of tumor necrosis factor ?-related conditions
    Patent number: 9447419
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: September 20, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Daniel A. Gamache, Steven T. Miller
  • RNAi-MEDIATED INHIBITION OF SPLEEN TYROSINE KINASE-RELATED INFLAMMATORY CONDITIONS
    Publication number: 20160257963
    Abstract: RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
    Type: Application
    Filed: May 17, 2016
    Publication date: September 8, 2016
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • INTERFERING RNA DELIVERY SYSTEM AND USES THEREOF
    Publication number: 20160257956
    Abstract: The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.
    Type: Application
    Filed: April 19, 2016
    Publication date: September 8, 2016
    Inventors: Ying Yu, Jon E. Chatterton
  • RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesis
    Patent number: 9422556
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: August 23, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Jon E. Chatterton, Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers
  • RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
    Patent number: 9371529
    Abstract: RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: June 21, 2016
    Assignee: Arrowhead Research Corporation
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY
    Publication number: 20160151514
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.
    Type: Application
    Filed: February 9, 2016
    Publication date: June 2, 2016
    Inventor: Jon E. Chatterton
  • Interfering RNA delivery system and uses thereof
    Patent number: 9347062
    Abstract: The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: May 24, 2016
    Assignee: Arrowhead Research Corporation
    Inventors: Ying Yu, Jon E. Chatterton
  • INTERFERING RNA DELIVERY SYSTEM AND USES THEREOF
    Publication number: 20160095937
    Abstract: The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.
    Type: Application
    Filed: December 7, 2015
    Publication date: April 7, 2016
    Inventor: Jon E. Chatterton
  • Low density lipoprotein receptor-mediated siRNA delivery
    Patent number: 9289514
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: March 22, 2016
    Assignee: Arrowhead Research Corporation
    Inventor: Jon E. Chatterton
  • RNAi-MEDIATED INHIBITION OF HISTAMINE RECEPTOR H1-RELATED CONDITIONS
    Publication number: 20160053270
    Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
    Type: Application
    Filed: November 2, 2015
    Publication date: February 25, 2016
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • Interfering RNA delivery system and uses thereof
    Patent number: 9233170
    Abstract: The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: January 12, 2016
    Assignee: Arrowhead Research Corporation
    Inventor: Jon E. Chatterton
  • RNAi-MEDIATED INHIBITION OF CONNEXIN 43 FOR TREATMENT OF IOP-RELATED CONDITIONS
    Publication number: 20160002638
    Abstract: RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
    Type: Application
    Filed: September 21, 2015
    Publication date: January 7, 2016
    Inventors: Jon E. Chatterton, Abbot F. Clark, Martin B. Wax
  • RNAi-mediated inhibition of histamine receptor H1-related conditions
    Patent number: 9206428
    Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: December 8, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-Related Inhibition of TNF-alpha Signaling Pathway for Treatment of Ocular Angiogenesis
    Publication number: 20150344886
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
    Type: Application
    Filed: August 17, 2015
    Publication date: December 3, 2015
    Inventors: Jon E. Chatterton, Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers
  • TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
    Publication number: 20150315592
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.
    Type: Application
    Filed: July 16, 2015
    Publication date: November 5, 2015
    Inventors: Jon E. Chatterton, Abbot F. Clark
  • RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions
    Patent number: 9173896
    Abstract: RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: November 3, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: Jon E. Chatterton, Abbot F. Clark, Martin B. Wax
  • siRNA targeting VEGFA and methods for treatment in vivo
    Patent number: 9150862
    Abstract: Vascular endothelial growth factor A (VEGFA) is a chemical signal produced by cells that stimulates the growth of new blood vessels, and overexpression of VEGFA can lead to undesirable physiological conditions. Through the identification of new siRNA and modifications that improve the silencing ability of these siRNA in vivo, therapeutic compositions and methods have been invented to address the problems associated with this overexpression.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: October 6, 2015
    Assignees: Thermo Fisher Scientific Inc., Arrowhead Research Corporation
    Inventors: Anja Smith, Angela Reynolds, Jon E. Chatterton, Xinyu Zhang